Cited 0 time in
The Orientation-Dependent Expression of Angiostatin-Endostatin Hybrid Proteins and Their Characterization for the Synergistic Effects of Antiangiogenesis
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Paek, Sun-Yeol | - |
| dc.contributor.author | Kim, Yong-Seok | - |
| dc.contributor.author | Choi, Shin-Geon | - |
| dc.date.accessioned | 2022-12-20T11:28:47Z | - |
| dc.date.available | 2022-12-20T11:28:47Z | - |
| dc.date.issued | 2010-10 | - |
| dc.identifier.issn | 1017-7825 | - |
| dc.identifier.issn | 1738-8872 | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/173622 | - |
| dc.description.abstract | Two angiostatic fusion proteins (hAE and hEA), differing in tandem connection manners, were constructed from human angiostatin (hAS) and endostatin (hES) proteins. These fusion proteins were then evaluated for synergistic antiangiogenic properties. The 65 kDa secreted fusion proteins, expressed in Pichia pastoris, were verified by both mass analysis and Western blotting assay. Luciferase reporter gene assay, using a VEGF promoter, revealed that the angiostatin endostatin fusion protein (hAE), and its corresponding fusion gene delivery on human microvascular endothelial cells (HMEC-1), resulted in a more potent synergistic antiangiogenic effect than the endostatin angiostatin fusion protein (hEA). These results suggest that the orientation of the fusion genes in hAS and hES might be an important factor in the development of therapeutic proteins. | - |
| dc.format.extent | 6 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | 한국미생물·생명공학회 | - |
| dc.title | The Orientation-Dependent Expression of Angiostatin-Endostatin Hybrid Proteins and Their Characterization for the Synergistic Effects of Antiangiogenesis | - |
| dc.type | Article | - |
| dc.publisher.location | 대한민국 | - |
| dc.identifier.doi | 10.4014/jmb.1004.04040 | - |
| dc.identifier.scopusid | 2-s2.0-78149484706 | - |
| dc.identifier.wosid | 000283628400009 | - |
| dc.identifier.bibliographicCitation | Journal of Microbiology and Biotechnology, v.20, no.10, pp 1430 - 1435 | - |
| dc.citation.title | Journal of Microbiology and Biotechnology | - |
| dc.citation.volume | 20 | - |
| dc.citation.number | 10 | - |
| dc.citation.startPage | 1430 | - |
| dc.citation.endPage | 1435 | - |
| dc.type.docType | Article | - |
| dc.identifier.kciid | ART001489796 | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.description.journalRegisteredClass | kci | - |
| dc.relation.journalResearchArea | Biotechnology & Applied Microbiology | - |
| dc.relation.journalResearchArea | Microbiology | - |
| dc.relation.journalWebOfScienceCategory | Biotechnology & Applied Microbiology | - |
| dc.relation.journalWebOfScienceCategory | Microbiology | - |
| dc.subject.keywordPlus | RESTRICTED REPLICATIVE ADENOVIRUS | - |
| dc.subject.keywordPlus | PICHIA-PASTORIS | - |
| dc.subject.keywordPlus | TUMOR-GROWTH | - |
| dc.subject.keywordPlus | GENE-TRANSFER | - |
| dc.subject.keywordPlus | FUSION GENE | - |
| dc.subject.keywordPlus | ANGIOGENESIS | - |
| dc.subject.keywordPlus | INHIBITION | - |
| dc.subject.keywordPlus | LEVEL | - |
| dc.subject.keywordPlus | DORMANCY | - |
| dc.subject.keywordAuthor | Angiogenesis inhibitor | - |
| dc.subject.keywordAuthor | angiostatin | - |
| dc.subject.keywordAuthor | endostatin | - |
| dc.subject.keywordAuthor | Pichia expression | - |
| dc.identifier.url | https://www.jmb.or.kr/journal/view.html?volume=20&number=10&spage=1430 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
